Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Achillion Pharmaceuticals |
---|---|
Information provided by: | Achillion Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT00037622 |
The purpose of this study is to determine the safety and antiviral HBV activity of ACH-126,443 (beta-L-Fd4C) in the treatment of Subjects of Previous Achillion-Sponsored Phase 1 and 2 Studies in Chronic Hepatitis B Infection.
Condition | Intervention |
---|---|
Chronic Hepatitis B |
Drug: ACH-126, 443 (beta-L-Fd4C) |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | An Open-Label Treatment Protocol to Provide Continued ACH-126,443 to Subjects of Previous Achillion-Sponsored Phase 1 and 2 Studies in Chronic Hepatitis B Infection |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria
Study ID Numbers: | ACH443-901 |
Study First Received: | May 17, 2002 |
Last Updated: | July 20, 2006 |
ClinicalTrials.gov Identifier: | NCT00037622 |
Health Authority: | United States: Food and Drug Administration |
E-antigen positive, treatment naïve chronic HBV infected, lamivudine resistant chronic Hepatitis B, Achillion |
Virus Diseases Hepatitis Liver Diseases Digestive System Diseases Hepatitis, Chronic |
Hepatitis B, Chronic Hepatitis B Lamivudine Hepatitis, Viral, Human DNA Virus Infections |
Hepadnaviridae Infections |